Bevacizumab versus Ranibizumab on As-Needed Treatment Regimen for Neovascular Age-Related Macular Degeneration in Turkish Patients

Table 2

The change in mean best corrected visual acuity from baseline to different time points.

Change in BCVA (LogMAR line)	Month 3	Month 6	Month 9	Month 12	Last followup
Bevacizumab group	1.6	1.9	1.9	1.9	1.8
Ranibizumab group	1.4	1.5	1.5	1.5	1.5
P value	0.7	0.6	0.5	0.5	0.6

BCVA: best corrected visual acuity; LogMAR: logarithm of the minimal angle of resolution.